Alnylam Pharmaceuticals Inc (ALNY) Q4 2019 Earnings Call Transcript
ALNY earnings call for the period ending December 31, 2019.
Alnylam Pharmaceuticals
ALNY
ALNY
$113.53
-$4.52
-3.8%
Price as of February 27, 2020, 3:32 p.m. EST
View Interactive ALNY Charts
A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.
Interactive Chart
News & Analysis: Alnylam Pharmaceuticals
The Fool has written over 200 articles on Alnylam Pharmaceuticals.
Alnylam Beats Revenue Estimates, but Misses on Earnings
Shares of the genetic disease specialist were essentially flat in late afternoon trading.
Why Alnylam Pharmaceuticals Rose 57.9% in 2019
All of the share price gains came after September -- and for good reason.
3 Rare Disease Drug Launches to Watch in 2020
Patients who inherit life-threatening blood disorders have some important new treatment options.
Here's Why Dicerna Pharmaceuticals Is Falling Today
What goes up must come down. But today's tumble means relatively little for investors with a long-term mindset.
Here's Why Alnylam Pharmaceuticals Rose 35.1% in November
The RNAi pioneer earned a surprise drug approval. It could have far-reaching implications for the company's future.
Does a Surprise Approval Make Alnylam Pharmaceuticals a Buy?
Investors were caught off guard when the genetic medicines company earned marketing approval for its second RNAi drug product sooner than expected.
5 New Drug Approvals the FDA Gave Top Priority
Here's why the FDA recently approved five new drugs way ahead of schedule.
Is Alnylam Stock a Good Buy Now?
This biotech's impressed the FDA, but what about shareholders?
![5916202_Givlaari_CartonVial_Angled[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F548920%2F5916202_givlaari_cartonvial_angled1.jpg&w=479&h=281&op=resize)
Second RNAi Drug Approved: Biotech Investors Should Pay Attention to This New Drug Class
Alnylam Pharmaceuticals is coming of age.
